Moventig (Naloxegol)

Naloxegol selectively blocks µ‑opioid receptors located in the gastrointestinal tract. This antagonism reverses the constipating effect of opioids on intestinal motility while leaving central opioid receptors untouched, allowing patients to maintain analgesia while improving bowel function.

The dosage of Moventig is determined by the prescribing healthcare professional based on the patient’s clinical condition, opioid regimen, and renal function. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Naloxegol in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Moventig, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moventig (Naloxegol) is a peripherally acting µ‑opioid receptor antagonist, differing from laxatives or stool softeners that act locally. Compared with other antagonists such as methylnaltrexone, Naloxegol is administered orally and does not require injection, offering a convenient option for many patients.

Store Moventig tablets at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in extreme heat or humidity, and keep out of reach of children.

Moventig is taken orally as a tablet, usually on an empty stomach at least one hour before or two hours after the first dose of an opioid analgesic. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include possible intestinal obstruction, severe abdominal pain, allergic reactions such as rash or swelling, and rare liver enzyme elevations. Patients should seek immediate medical attention if they experience any signs of obstruction or severe hypersensitivity.

Moventig is contraindicated in patients with known hypersensitivity to Naloxegol or any of its excipients, and in those taking strong CYP3A4 inhibitors such as ketoconazole or ritonavir. Caution is also advised for individuals with severe renal impairment or existing gastrointestinal obstruction.